OBJECTIVE: To examine whether insulinlike growth factor I (IGF I), IGF II and IGF binding protein 3 (IGFBP 3) in serum and peritoneal fluid (PF) correlate with the presence and severity of endometriosis. STUDY DESIGN: Case-control study including 29 patients with endometriosis and 15 controls. The revised American Fertility Society classification stages of I and II were pooled as early-stage (n = 15), and stages III and IV were taken as late stage (n = 14). Simultaneous sampling of blood and PF was performed during laparoscopy, and IGF I, IGF II and IGFBP 3 levels were determined by immunoradiometric assay. RESULTS: The serum levels of all three proteins were higher than PF levels except for a reversed IGF I PF: serum ratio in the early stage. There were no significant differences in IGF II and IGFBP 3 levels among the groups. The mean serum IGF I levels of controls and early-stage patients were significantly lower than those in the late stage. Also, mean PF IGF I levels in controls were significantly lower than in the late stage. CONCLUSION: IGF I may be an important mediator in the development and/or maintenance of endometriosis or progression to late-stage disease.
OBJECTIVE: To examine whether insulinlike growth factor I (IGF I), IGF II and IGF binding protein 3 (IGFBP 3) in serum and peritoneal fluid (PF) correlate with the presence and severity of endometriosis. STUDY DESIGN: Case-control study including 29 patients with endometriosis and 15 controls. The revised American Fertility Society classification stages of I and II were pooled as early-stage (n = 15), and stages III and IV were taken as late stage (n = 14). Simultaneous sampling of blood and PF was performed during laparoscopy, and IGF I, IGF II and IGFBP 3 levels were determined by immunoradiometric assay. RESULTS: The serum levels of all three proteins were higher than PF levels except for a reversed IGF I PF: serum ratio in the early stage. There were no significant differences in IGF II and IGFBP 3 levels among the groups. The mean serum IGF I levels of controls and early-stage patients were significantly lower than those in the late stage. Also, mean PF IGF I levels in controls were significantly lower than in the late stage. CONCLUSION:IGF I may be an important mediator in the development and/or maintenance of endometriosis or progression to late-stage disease.
Authors: Allison F Vitonis; Heather J Baer; Susan E Hankinson; Marc R Laufer; Stacey A Missmer Journal: Hum Reprod Date: 2010-02-19 Impact factor: 6.918
Authors: L V Farland; S A Missmer; A Bijon; G Gusto; A Gelot; F Clavel-Chapelon; S Mesrine; M C Boutron-Ruault; M Kvaskoff Journal: Hum Reprod Date: 2017-08-01 Impact factor: 6.918
Authors: Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull Journal: Cochrane Database Syst Rev Date: 2016-05-01
Authors: Costin Vlad Anastasiu; Marius Alexandru Moga; Andrea Elena Neculau; Andreea Bălan; Ioan Scârneciu; Roxana Maria Dragomir; Ana-Maria Dull; Liana-Maria Chicea Journal: Int J Mol Sci Date: 2020-03-04 Impact factor: 5.923